Gilead scores ex­pand­ed la­bel for he­pati­tis B drug Vem­lidy in chil­dren 6 years and old­er

The FDA ex­pand­ed the la­bel for Gilead’s he­pati­tis B drug Vem­lidy on Thurs­day to pa­tients as young as 6 years old.

Vem­lidy, or teno­fovir alafe­namide, is a once-dai­ly treat­ment for chron­ic he­pati­tis B that pulled in $862 mil­lion in sales for Gilead in 2023, up from $842 mil­lion in 2022.

The reg­u­la­tor orig­i­nal­ly ap­proved the ther­a­py in 2016 for adults with chron­ic he­pati­tis B in­fec­tions and com­pen­sat­ed liv­er dis­ease. Then in 2022, the la­bel was ex­pand­ed to in­clude pa­tients who are at least 12 years old with the in­fec­tion and com­pen­sat­ed liv­er dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER